Judge Rejects Bid by Amgen to Block Biosimilar Drug by Novartis
Novartis's drug, Zarxio, contains the same active ingredient as Amgen's Neupogen, and once released would become the first biosimilar in the United States.
Novartis's drug, Zarxio, contains the same active ingredient as Amgen's Neupogen, and once released would become the first biosimilar in the United States.
